Feature | February 01, 2013

Direct Flow Medical Receives CE Mark for Transcatheter Aortic Heart Valve

Clinicians can fully assess and optimize patient outcomes before valve is secured in place

Direct Flow Medical Transcatheter Aortic Valve System CE mark

February 1, 2013 — Direct Flow Medical Inc. has received CE mark for its distinctive transcatheter aortic heart valve with metal-free frame and low-profile transfemoral delivery system. The Direct Flow Medical transcatheter aortic valve system is designed to virtually eliminate aortic regurgitation by allowing complete assessment of hemodynamic performance, repositioning and retrieval after the valve is fully deployed in the native valve annulus. The double ring design of the valve creates a tight and durable seal around the annulus. The system is designed to improve the long term survivability of patients by resolving the clinical issues associated with current commercial valves.

Two sizes of valves – 25 mm and 27 mm – will be commercially available in Europe immediately; both are delivered via a flexible, 18 French system.

Post-procedural aortic regurgitation has been shown to be a predictor of long-term mortality.[1] The 30-day, core-lab adjudicated results from the DISCOVER trial, presented at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) conference, showed that the Direct Flow Medical system achieved 97 percent freedom from all-cause mortality, with 97 percent of patients experiencing no or mild aortic regurgitation.[2]

In addition, total average procedure time was 41.8 minutes with no post-dilatations required.[2] The DISCOVER trial is a prospective multicenter study conducted at seven leading European cardiology centers. Data from Direct Flow’s first-in-man study, presented at TCT 2012, showed a four-year survival rate of 54 percent, with 80 percent of patients exhibiting no aortic regurgitation, and 20 percent showing trace amounts.[4]

“The Direct Flow Medical system is unique in many ways that combine to virtually eliminate aortic regurgitation, creating greater confidence in the outcome,” said Joachim Schofer, M.D., of the Medical Care Center, Hamburg, Germany, and co-principal investigator for the DISCOVER trial.

“Its novel design enables us to fully assess outcomes and adjust or retrieve the valve at any time during the procedure, without creating hemodynamic stress for the patient,” Schofer added. “This keeps the procedure calm throughout. Delivery is also easy, as the flexible, low-profile design has enabled me to navigate vessels as small as 5.2 mm without vascular complications.” 

The Direct Flow Medical system also reduces procedural risk by eliminating the need for rapid pacing during deployment[3] and post-dilatation, which are common with other valves and can compromise hemodynamic stability during deployment and positioning.

To support European commercialization, the company has also announced the appointment of Dan Rose as vice president of sales and marketing. Most recently, Rose was vice president of commercial operations for Sequana Medical, a Swiss medical device company developing proprietary implantable pump systems. Prior to that, Rose held a number of sales and marketing leadership positions at Medtronic in Europe in both the interventional cardiology and cardiac surgery businesses.

“Dan is an experienced medical device executive who understands how to market novel cardiovascular technologies and commercialize in diverse and competitive international markets,” said Bernard Lyons, CEO of Direct Flow Medical. “His experience positioning innovative cardiovascular devices to drive clinical adoption will contribute to our success as we launch in Europe.”

The benefits of the Direct Flow Medical transcatheter aortic valve system are enabled by its design, which features a distinctive, metal-free frame. Rather than a metal stent, the system incorporates a polymer frame, which is expanded using pressurized saline and contrast for placement, assessment and repositioning. The saline/contrast solution is easily exchanged for a quick-curing polymer that solidifies and secures the valve in place once optimal positioning is reached. The double-ring design of the valve creates a tight and durable seal around the annulus. Three hollow positioning wires allow for the fluid exchange and also uniquely enable distal, proximal and planar repositioning. The metal-free design enables an 18 French, fully sheathed delivery system that has been proven to minimize vascular complications and improve hemodynamic outcomes.[2]

For more information: www.directflowmedical.com

References:

[1] Kodali S, Williams M  Smith C, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012;366(18):1686-1695.

[2] Schofer J, Fajadet J, Colombo A, et al. 30-day outcome of the 18F-Direct Flow Medical valve in patients with aortic stenosis – results from the DISCOVER trial. JACC 2012;60(17):B236

[3] Schofer J, Schlüter M Treede H, et al. Retrograde transarterial implantation of a nonmetallic aortic valve prosthesis in high-surgical-risk patients with severe aortic stenosis – A first-in-man feasibility and safety study. Circ Cardiovasc Intervent 2008;1:126-133.

[4] Bijuklic K, Tuebler T  Treede H, et al. Long term performance of a transfemorally implantable nonmetallic, retrievable and repositionable aortic valve in patients with severe aortic stenosis - 4 year follow-up of the 22F-Direct Flow Medical valve. JACC 2012;60(17):B236.

Related Content

 Retired National Football League (NFL) star Ed White, the former Chargers guard and four-time Pro Bowler, waited until the FDA approved TAVR for low-risk patients like himself to avoid open-heart surgery.

Retired National Football League (NFL) star Ed White, the former Chargers guard and four-time Pro Bowler, waited until the FDA approved TAVR for low-risk patients like himself to avoid open-heart surgery.

Feature | Heart Valve Technology | October 29, 2019
October 29, 2019 — When Scripps cardiologists discovered early in 2019 that retired National Football League (NFL) gr
A Sapien 3 TAVR valve in position as seen under GE Assist guidance on angiography. Study Finds Sustained Benefit for TAVR vs. SAVR at One Year. #TCT2019 #TCT19

A Sapien 3 TAVR valve in position as seen under GE Assist guidance on angiography.

News | Heart Valve Technology | October 04, 2019
October 4, 2019 – A new analysis of the PARTNER 3 Trial data found a modest, but significant, improvement in one-year
Five-year results from the PARTNER 2A Trial found patients with severe aortic stenosis (AS) and intermediate surgical risk who underwent Sapien 3 transcatheter aortic valve replacement (TAVR) had similar rates of death and disabling stroke compared to those who had surgical aortic valve replacement (SAVR). However, TAVR using a transthoracic approach had poorer outcomes compared to SAVR. #TCT2019
News | Heart Valve Technology | October 03, 2019
October 3, 2019 – Five-year results from the PARTNER 2A Trial found patients with severe aortic stenosis (AS) and int
The Boston Scientiofic Acurate Neo TAVR valve did not meet non-inferiority to the Sapien 3 valve in patients with severe aortic stenosis. #TAVR #TCT2019
News | Heart Valve Technology | October 02, 2019
October 2, 2019 – The first randomized trial to compare the safety and efficacy of the new Boston Scientific Acurate
The Portico FDA investigational device exemption (IDE) study found that 30-day safety and one-year effectiveness outcomes of a novel self-expanding transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis (AS) at high or extreme-risk for surgery was noninferior to contemporary FDA-approved TAVR systems. #TAVR #TCT2019
News | Heart Valve Technology | October 02, 2019
October 2, 2019 – The Abbott Portico FDA investigational device exemption (IDE) study found that 30-day safety and on
Medtronic Launches Evolut Pro+ TAVR System
Technology | Heart Valve Technology | September 24, 2019
Medtronic announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Evolut Pro+ transcatheter...
Reducing Secondary Mitral Regurgitation in Heart Failure Does Not Improve Two-year Outcomes
News | Heart Valve Technology | September 11, 2019
Percutaneous reduction of secondary mitral regurgitation in patients with heart failure does not lower death and...
Abbott Launches Pivotal Trial of TriClip Tricuspid Valve Repair System
News | Heart Valve Technology | September 05, 2019
Abbott announced the launch of the company's TRILUMINATE Pivotal trial evaluating the safety and effectiveness of its...
Overlay Init